Table 2 Summary of primary and secondary outcomes
Outcome | 3-weekly docetaxel (95% CI) | 2-weekly docetaxel (95% CI) | P-value | Hazard ratio (95% CI) | P-value |
|---|---|---|---|---|---|
Overall PSA response | 0.683 | ||||
Objective responsea | 12 (50.0%) | 11 (45.8%) | .. | .. | .. |
Stable disease | 10 (41.7%) | 9 (37.5%) | .. | .. | .. |
Disease progression | 2 (8.3%) | 4 (16.7%) | .. | .. | .. |
Median response duration months, (95% CI) | 4.0 (3.2–8.1) | 3.7 (2.7–6.0) | 0.342 | ||
Median TTTF, months, (95% CI) | 4.5 (3.1–5.9) | 3.9 (3.2–4.6) | 0.542 | 1.2 (0.7–2.2) | 0.551 |
Median TTP, months, (95% CI) | 5.0 (3.9–6.1) | 4.2 (3.5–4.9) | 0.530 | 1.2 (0.6–2.3) | 0.536 |